Ambreen Mohamed, MD
Cardiovascular Disease · Independence, MONPI 1437443637
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Novartis accounts for 77.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $7,766 and has fallen 99.6% since, to $29 in 2025.
Across 56 payments — averaging $160.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- Abbott$876
- Amgen$192
- Boehringer Ingelheim$141
- Amarin Pharma, Inc.$123
- W. L. Gore & Associates, Inc.$102
- plus $589 from 15 others
What the payments were for
- Consulting fees$5,32559%
- Travel & lodging$2,09523%
- Food & beverage$1,56917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $6,965 |
| Abbott | 10 | $876 |
| Amgen | 4 | $192 |
| Boehringer Ingelheim | 6 | $141 |
| Amarin Pharma, Inc. | 1 | $123 |
| W. L. Gore & Associates, Inc. | 1 | $102 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $95 |
| Johnson & Johnson | 3 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Lexicon Pharmaceuticals, Inc. | 2 | $46 |
| Merck | 2 | $45 |
| Novo Nordisk | 2 | $43 |
| Lilly USA, LLC | 2 | $36 |
| Boston Scientific | 2 | $34 |
| Bridgebio Pharma, Inc. | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Philips North America LLC | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Medtronic | 1 | $19 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$6,965
- MitraClip System$602
- Vascepa$123
- Repatha$123
- VIABAHN VBX Balloon Expandable Endoprosthesis$102
- ENTRESTO$100
How this compares
$8,990 in reported general payments places this provider in the 75th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 37 | $453 |
| Rosuvastatin Calcium | 18 | $247 |
| Atorvastatin Calcium | 34 | $179 |
| Carvedilol | 14 | $126 |
| Amlodipine Besylate | 13 | $71 |
| Metoprolol Tartrate | 16 | $15 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Independence
- Stephen DicksonIndependence$98K
- Thao DuongIndependence$27K
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James FairlambColumbia$342K
- James EllisonChesterfield$267K
- Osler Jay GuzonSaint Louis$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.